LQDA — Liquidia Corporation

Liquidia Corporation (LQDA) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Product Sales: $51.7 million for YUTREPIA in Q3 2025, marking a strong performance in its first full quarter post-launch.
• Net Loss: $3.6 million; however, on a non-GAAP basis, Liquidia reported positive adjusted EBITDA of $10.1 million.
• Cash Position: $157.5 million at the end of the quarter, with September marking the first month of positive net cash flow, adding $5 million in net cash.
• Prescription Metrics: Over 2,000 unique prescriptions and 1,500 active patients initiated therapy, with an 85% referral-to-start conversion rate.

2. Strategic Updates and Business Highlights

• Product Launch: YUTREPIA is gaining traction in the market, with significant uptake among both new and transitioning patients. Approximately 75% of patients are new to prostacyclin therapies.
• Market Positioning: Liquidia aims to redefine the standard of care for inhaled treprostinil, focusing on ease of use, tolerability, and patient compliance.
• Clinical Development: Plans to initiate niche open-label studies to expand YUTREPIA's clinical utility, including studies in PAH patients transitioning from oral therapies and potential studies in IPF and PPF.
• Next-Generation Product: Development of L606, a sustained-release formulation of inhaled treprostinil, is underway with a pivotal study (RESPIRE) expected to start enrollment in H1 2026.

3. Forward Guidance and Outlook

• Liquidia expects to maintain its positive cash flow trajectory into 2026 while reinvesting in R&D to support long-term growth.
• The company is focused on expanding YUTREPIA's market presence and indications, with continued emphasis on building prescriber awareness and patient access.

4. Bad News, Challenges, or Points of Concern

• Litigation Risks: Ongoing litigation with United Therapeutics raises uncertainties regarding potential outcomes, which could impact market access and product positioning.
• Payer Coverage: While contracts have been signed with major payers, the competitive landscape remains challenging, particularly with other companies entering contracts that could affect YUTREPIA's market share.
• Market Dynamics: There is potential for seasonality and ordering choppiness as the product continues to establish itself in the market.

5. Notable Q&A Insights

• Patient Uptake Drivers: The strong uptake of YUTREPIA is attributed to its unique product profile and the ability to transition patients from oral therapies, with PAH being the primary indication.
• Payer Dynamics: Approximately 85% of referrals are converting to prescriptions, indicating effective market access strategies. The company is working to ensure patients are not blocked by contracting issues.
• Litigation Impact: The management believes that the ongoing litigation is not significantly affecting physician prescribing behavior, as their primary focus remains on patient outcomes.
• Future Patient Projections: While management refrained from providing specific patient number forecasts, they highlighted strong brand awareness and high pull-through rates as indicators of continued growth potential.

Overall, Liquidia's Q3 2025 results reflect a robust launch of YUTREPIA, with promising financial metrics and strategic initiatives aimed at sustaining growth, despite facing litigation and competitive challenges.